|Abbvie M15-554||PSA - Psoriatic Arthrtis||A Phase 3, Randomized, Double-Blind, Study Comparing ABT-494 to Placebo in Subjects with Active Psoriatic Arthritis Who Have a History of Inadequate Response to at Least One Biologic Disease Modifying Anti-Rheumatic Drug (bDMARD) Budget amended to enroll up to 20 patients||$1015||Apply|
|Abbvie M15-572||PSA - Psoriatic Arthrtis||A Phase 3, Randomized, Double-Blind Study Comparing Upadacitinib (ABT-494) to Placebo and to Adalimumab (Humira) in Subjects with Active Psoriatic Arthritis Who Have a History of Inadequate Response to at Least One Non-Biologic Disease Modifying Anti-Rheumatic Drug (DMARD)||$1300||Apply|
|GSK BELIEVE||Lupus||A Phase 3, Multi-Center, Randomized, Double-Blind, Placebo-Controlled, 104-Week Study to Evaluate the Efficacy and Safety to Belimumab Administered in Combination with Rituximab to Adult Subjects with Systemic Lupus Erythematosus (SLE)||$1375||Apply|
|Novartis ASLeap||AS - Ankylosing Spondylitis||A randomized, double-blind, parallel-group, multicenter study of secukinumab to compare 300 mg and 150 mg at Week 52 in patients with Ankylosing Spondylitis who are randomized to dose escalation after not achieving inactive disease during an initial 16 weeks of open-label treatment with secukinumab 150 mg (ASLeap)||$0||Apply|
|CREDO 3||RA - Rheumatoid Arthritis||The purpose of this study is to determine how safe and effective the study drug Olokizumab is, in patients with Rheumatoid Arthritis (RA) who are already receiving, but not fully responding to treatment with an existing medication called a tumour necrosis factor alpha inhibitor||$0||Apply|
|CREDO 2||RA - Rheumatoid Arthritis||A Randomized, Double-Blind, Parallel-Group, Placebo- and Active-Controlled, Multicenter Phase III Study of the Efficacy and Safety of Olokizumab in Subjects with Moderately to Severely Active Rheumatoid Arthritis Inadequately Controlled by Methotrexate Therapy||$0||Apply|
|CREDO 4||RA - Rheumatoid Arthritis||A Multicenter Open Label, Phase III Study of the Efficacy and Safety of Olokizumab in Subjects with Moderately to Severly Active Rheumatoid Arthritis. CREDO 4. Dated 4-28-16 CL04041024||$0||Apply|
Dayton, Ohio has a metropolitan area population of over 800,000 people!
Below is a list of upcoming studies, or medical conditions which we regularly contract studies. Enrollment periods vary and some studies close enrollment very quickly. To be notified of new studies, use the registration form to get email or phone updates when new studies become available for conditions which you have.
- Hypertension (High Blood Pressure)
- OA - Osteo Arthrtis
Register to receive updates on upcoming studies for which you may qualify for. You may choose to be contacted by phone, text message, or email.